1146. Effectiveness of Ultraviolet Irradiation on Candida auris: A Laboratory Study.
Session: Poster Abstract Session: Healthcare Epidemiology: Environmental and Occupational Health
Friday, October 5, 2018
Room: S Poster Hall
  • CA poster 2.pdf (1.9 MB)
  • Background:

    Candida auris is a multidrug-resistant yeast which persists on healthcare surfaces for prolonged periods of time and is an emerging pathogen in hospitals. It has been linked to healthcare-associated infection (HAI) through surface transmission. Mobile ultraviolet (UV) light emitting devices from mercury sources have been shown to be effective in reducing C. auris bioburden but require prolonged exposure. In this study we demonstrate the efficacy of an UV emitting device used in our hospital for terminal disinfection on C. auris.


    Two C. auris strains (AR-381-CAU-01 & CAU-02) isolates obtained from Centers for Disease Prevention and Control (CDC) were used along with a Candida albicans (C. albicans) strain. An organism load of 10ul containing 10^6 Colony Forming Unit (CFU) was spread on a 20mm diameter stainless steel coupon and exposed to the UV source from a pulsed xenon device at 5 feet distance and 4 feet height for 5, 10 and 30 minutes. Killing efficacy in terms of log reduction was calculated in comparison to untreated control coupons.


    Mean CFU Log10 reduction for C. albicans, CAU-01, and CAU-02 was 0.547, 1.051, and 0.952 at 5 minutes; 1.412, 1.975, and 1.879 at 10 minutes; and 2.639, 3.971, and 4.145 at 30 minutes, respectively. Figure 1 describes the mean log10 reduction as well as the minimum and maximum log reduction by isolates.


    Our study demonstrates the UV from a pulsed xenon device is effective in reducing the C. auris on stainless steel coupons. Similar to previously published data on reduction of C. auris by other UV sources, extended exposure is required to achieve a higher log reduction of Candida auris. We did not have any C. auris clinical infections to assess efficacy of UV on HAI reduction.

    Gennifer Garmon, MD, Infectious Diseases, Baylor Scott & White Memorial Hospital, Temple, TX, Dhammika Navarathna, DVM, MS, PhD, Central Texas Veterans Health Care System, Temple, TX, John Coppin, MPH, Research, Central Texas Veterans Healthcare System, Temple, TX, Marjory Williams, PhD, Central Texas Veterans Healthcare System, Temple, TX and Chetan Jinadatha, MD, MPH, Infectious Disease Division, Central Texas Veterans Health Care System, Temple, TX


    G. Garmon, None

    D. Navarathna, None

    J. Coppin, None

    M. Williams, None

    C. Jinadatha, Xenex Healthcare Service: Grant Investigator , Research grant .

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.